SCHEMBL2173086

SCHEMBL2173086

COC(=O)c1cc(OCc2ccccc2)c2cc(F)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
HPGD P15428 2/20 0.54
MRGPRX4 Q96LA9 4/20 0.49
FFAR4 Q5NUL3 1/20 0.48
PLA2G2A P14555 2/20 0.47
SMPD1 P17405 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MAPT P10636 3/20 0.45
RAB9A P51151 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
PPIA P62937 1/20 0.45
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PTGER1 P34995 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29230634 0.89 KMT2A (0.49) LMNAMRGPRX4MAPTRAB9AL3MBTL1
SCHEMBL31667762 0.88 PTGER1 (0.56) MRGPRX4PTGER1
SCHEMBL20975261 0.86 HPGD (0.60) LMNAHPGDMRGPRX4SMPD1HDAC1
SCHEMBL2175029 0.82 LMNA (0.43) LMNAMRGPRX4FFAR4PLA2G2AMAPT
SCHEMBL25254997 0.81 CYP3A4 (0.51) LMNAHPGDPLA2G2AMAPTRAB9A
SCHEMBL29230493 0.80 HPGD (0.53) LMNAHPGDMRGPRX4SMPD1HDAC1
SCHEMBL30582413 0.79 MAPT (0.60) LMNAHPGDMRGPRX4SMPD1HDAC1
SCHEMBL26129071 0.79 MAPT (0.60) LMNAHPGDMRGPRX4SMPD1HDAC1
SCHEMBL27841440 0.79 PTGDR2 (0.48) LMNAMRGPRX4FFAR4MAPTL3MBTL1
SCHEMBL25721332 0.79 HPGD (0.54) LMNAHPGDMRGPRX4SMPD1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2791111-B1 [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS HOFFMANN LA ROCHE (CH) 2017-01-18 EP disclosed
EP-2791111-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F.HOFFMANN-LA ROCHE AG (CH) 2014-10-22 EP disclosed
CN-102216265-B Naphthylacetic acid HOFFMANN LA ROCHE 2014-04-30 CN disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
WO-2013087544-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2013-06-20 WO disclosed
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HOFFMANN-LA ROCHE INC. (US) 2013-06-13 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125058-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1698/4885HPGD 384/4885MRGPRX4 40/4885
US-20100125061-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1535/4885HPGD 429/4885MRGPRX4 97/4885
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1827/4885HPGD 312/4885MRGPRX4 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.